At the time of writing, Ionis Pharmaceuticals Inc [IONS] stock is trading at $59.35, down -1.88%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IONS shares have gain 38.83% over the last week, with a monthly amount glided 37.86%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on September 03, 2025, when BMO Capital Markets upgraded its rating to a Outperform but kept the price target unchanged to $70 for it. Previously, Morgan Stanley upgraded its rating to Overweight on July 31, 2025, and kept the price target unchanged to $62. On July 01, 2025, upgrade upgraded it’s rating to Overweight but maintained its price target of $57 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $45 on April 07, 2025. Redburn Atlantic initiated its recommendation with a Neutral and recommended $39 as its price target on March 31, 2025. BMO Capital Markets downgraded its rating to Market Perform for this stock on August 02, 2024, and downed its price target to $60. In a note dated July 24, 2024, Leerink Partners upgraded an Outperform rating on this stock and boosted its target price from $53 to $62.
For the past year, the stock price of Ionis Pharmaceuticals Inc fluctuated between $23.95 and $62.08. Currently, Wall Street analysts expect the stock to reach $76.43 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $59.35 at the most recent close of the market. An investor can expect a potential return of 28.78% based on the average IONS price forecast.
Analyzing the IONS fundamentals
According to Ionis Pharmaceuticals Inc [NASDAQ:IONS], the company’s sales were 944.48M for trailing twelve months, which represents an 100.69% jump. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.45 and Total Capital is -0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 58.55 points at the first support level, and at 57.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 60.45, and for the 2nd resistance point, it is at 61.55.
Ratios To Look Out For
It is important to note that Ionis Pharmaceuticals Inc [NASDAQ:IONS] has a current ratio of 2.87. In addition, the Quick Ratio stands at 2.86 and the Cash Ratio stands at 0.33. Considering the valuation of this stock, the price to sales ratio is 10.02, the price to book ratio is 14.96.
Transactions by insiders
Recent insider trading involved Swayze Eric, EVP Research, that happened on Sep 02 ’25 when 11130.0 shares were sold. Director, WENDER JOSEPH H completed a deal on Sep 02 ’25 to sell 16800.0 shares. Meanwhile, Director WENDER JOSEPH H sold 11200.0 shares on Sep 03 ’25.
